When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion share repurchase program was completed in the fourth ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.